Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.60 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.54 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16823716 | 1.00 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3PBRM1 | |
| SCHEMBL410960 | 0.87 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3PBRM1 | |
| SCHEMBL410961 | 0.87 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3PBRM1 | |
| SCHEMBL30047902 | 0.87 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3PBRM1 | |
| SCHEMBL10130365 | 0.81 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL10130302 | 0.81 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL5670717 | 0.81 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL3641602 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL2104033 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL496236 | 0.80 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704105-B9 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-3704105-B1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD (GB) | 2024-10-16 | — | — | EP | disclosed |
| CN-111566099-B | Antibacterial compounds | 迪斯库瓦有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2022-11-24 | — | — | US | disclosed |
| US-11345694-B2 | Antibacterial compounds | DISCUVA LTD. (GB) | 2022-05-31 | — | — | US | disclosed |
| CN-109180667-B | 8- (benzofuran-5-yl) benzoxazinone derivative and application thereof | 湖南大学 | 2021-08-06 | — | — | CN | disclosed |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | DISCUVA LTD. (GB) | 2021-06-03 | — | — | US | disclosed |
| CN-110950773-B | Biphenyldiphenol amide derivative and application thereof as anticancer drug | 湖南大学 | 2021-05-25 | — | — | CN | disclosed |
| EP-3704105-A1 | ANTIBACTERIAL COMPOUNDS | Discuva Ltd. (GB) | 2020-09-09 | — | — | EP | disclosed |
| CN-111566099-A | Antibacterial compounds | 迪斯库瓦有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
| WO-2010111626-A2 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| EP-1015437-B1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AG (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-6365736-B1 | TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-04-02 | — | — | US | disclosed |
| EP-1015437-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012915-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345694-B2 | Antibacterial compounds | CFTR, MRPL21, NQO1 | PARP1 3028/4885PDE3B 719/4885PDE3A 1268/4885 |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885PDE3B 1682/4885PDE3A 1463/4885 |
| US-20220372027-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NRDC, PGLS | PARP1 1809/4885PDE3B 2244/4885PDE3A 2983/4885 |
| US-20210163460-A1 | ANTIBACTERIAL COMPOUNDS | CFTR, MRPL21, NQO1 | PARP1 3028/4885PDE3B 719/4885PDE3A 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.